Antiviral therapy for XXXX papillomaviruses: rational and prospects.

@entity1083 @entity1 @entity189 @entity1082
OBJECTIVE: To review the basic virology of @entity1082 ) and the natural history of @entity1083 and to discuss current and potential therapies. DATA SOURCES: The MEDLINE database (1966 to 1994) was searched to identify English-language articles and abstracts on HPV biology and antiviral chemotherapy. STUDY SELECTION: Peer-reviewed basic science and clinical research studies on the molecular, cellular, and @entity1 biology of @entity1083 . DATA EXTRACTION: Summaries of data from research studies on the biology of @entity1083 and information from review articles on the basic and applied pharmacology of antiviral agents. DATA SYNTHESIS: @entity1083 are very common. @entity1082 infections may be asymptomatic or may be manifested in various benign or malignant lesions, most notably anogenital @entity189 . Currently, therapeutic options for @entity1083 are limited, expensive, and often ineffective. By understanding the basic virology and natural history of @entity1083 , potential sites for pharmacologic intervention can be identified. Although currently available antiviral compounds are inactive against HPV, they serve as models for the rational design of HPV antiviral drugs. CONCLUSIONS: Although @entity1083 causes substantial morbidity and expense, uniformly effective therapy for @entity1083 is not currently available. Several processes in the @entity1083 cycle are appropriate targets for the development of antiviral agents. The development of compounds active against HPV could prevent the benign and malignant diseases associated with @entity1083 .
